What smart money is saying about ICON plc
7 funds in our archive have pitched ICON plc — most recently Orbis International Equity in December 2025.
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It offers clinical development services, including early development, patient recruitment and retention, strategy and analytics, late phase research, data and technology solution, and consulting and analytics services. The company's clinical development services also comprise medical imaging, clinical research and laboratory services, project management, site monitoring and management services, data management, biostatistics and programming, medical writing and publishing, medical affair, endpoint adjudication/data monitoring committees, pharmacovigilance, interactive response technologies, clinical supplies management, strategic regulatory, medical communication, and consulting and advisory services. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. The company was incorporated in 1990 and is headquartered in Dublin, Ireland.
Fund coverage · 7 theses
- Orbis International EquityDecember 2025
ICON plc is a leading CRO trading at a depressed multiple due to temporary headwinds but supported by strong secular demand for healthcare innovation.
Read the full thesis - LRT Capital ManagementJune 2025
ICON Public Limited Company is a leading global Contract Research Organization that specializes in drug and device development services, leveraging its scale, expertise, and technology to enhance efficiency and success in the complex clinical trial process for the biopharma industry.
Read the full thesis - Harris Oakmark Concentrated StrategyJune 2025
ICON PLC is a leading contract research organization that presents a buying opportunity due to its low earnings multiple and potential for recovery in biopharma R&D spending.
Read the full thesis - GreenskeeperMarch 2025
Icon PLC (ICLR) is a leading contract research organization that will benefit from ongoing development of new drugs and medical devices, despite current regulatory uncertainties.
Read the full thesis - Parnassus Mid Cap Growth FundMarch 2025
ICON is a leading CRO poised for growth as R&D spending rebounds and it gains market share following a recent stock sell-off.
Read the full thesis - Brown Advisory Large Cap Sustainable ValueMarch 2025
ICON Plc is a leading contract research organization benefiting from sustainable cash flow and attractive valuation despite recent industry pressures.
Read the full thesis - Sequoia FundDecember 2024
ICON plc is a leading Contract Research Organization positioned to benefit from the ongoing demand for drug development despite recent financial challenges.
Read the full thesis
Read every full thesis on ICON plc
Unlock all 7 theses — the full reasoning behind what funds are buying, plus unlimited access to the entire archive.
View plans→